ICH Good Clinical Priniciples Part 5 Flashcards
With regard to liability claims that may arise against the investigator/institution the sponsor should
a) Provide indemnification
b) Provide insurance where possible
c) Specify compensation for trial subjects in the event of trial related injury
d) All of the above
With regard to liability claims that may arise against the investigator/institution the sponsor should
d) All of the above
a) Provide indemnification
b) Provide insurance where possible
c) Specify compensation for trial subjects in the event of trial related injury
The sponsor should ensure that in planning for a clinical trial the sponsor should ensure all of the following except
a) Sufficient safety and efficacy data is available from non clinical studies
b) Pilot studies in human subjects have been performed
c) That the drug will be safe in pregnant women and children
d) Data to support route, dosage and duration of treatment is available.
The sponsor should ensure that in planning for a clinical trial the sponsor should ensure all of the following except
c) That the drug will be safe in pregnant women and children
With regard to access to medical records during a clinical trial
a) The subject should consent in writing to medical record access
b) Access should be guaranteed for monitoring, audits, IRB review and regulatory inspection
c) Access should be in accord with prevailing federal and state laws
d) All of the above
With regard to access to medical records during a clinical trial
d) All of the above
a) The subject should consent in writing to medical record access
b) Access should be guaranteed for monitoring, audits, IRB review and regulatory inspection
c) Access should be in accord with prevailing federal and state laws
The monitor should ensure all of the following except (check all that apply)
a) Informed consent was obtained before subject participation
b) The investigator receives the investigators brochure
c) Protocol procedures are performed is specified in the protocol’s schedule of assessments
d) Only eligible subjects are enrolled
e) CRFs are accurate and supported by sourced documents
f) Participate in the meetings between the investigator and staff
g) Contribute to the investigator’s recruitment efforts
h) Failed visits, test and procedures not performed are reported on CRFs i Adverse events are reported to the IRB and sponsor in timely fashion
The monitor should ensure all of the following except (check all that apply)
f) Participate in the meetings between the investigator and staff
g) Contribute to the investigator’s recruitment efforts
The monitoring report should include
a) Name of the investigator
b) Significant findings, deviations and deficiencies
c) Actions needed to secure compliance
d) All of the above
The monitoring report should include
d) All of the above
a) Name of the investigator
b) Significant findings, deviations and deficiencies
c) Actions needed to secure compliance
With regard to access to the sponsors audit report by regulatory authority ICH advises
a) Regulatory authority should not routinely request access to the audit report
b) Require the audit report to be part of he study binder
c) Ask to see the internal audit reports prior to commencing their audits
d) Record the absence of an internal audit report a deficiency
With regard to access to the sponsors audit report by regulatory authority ICH advises
a) Regulatory authority should not routinely request access to the audit report
Toxicological effects in the investigator’s brochure should include
a) Carcinogenicity
b) Irritancy
c) Reproductive toxicity
d) Genotoxicity and mutagenicity
e) All of the above
Toxicological effects in the investigator’s brochure should include
e) All of the above
a) Carcinogenicity
b) Irritancy
c) Reproductive toxicity
d) Genotoxicity and mutagenicity
The investigator’s brochure should include all of the following except
a) Marketing experience in foreign countries
b) Summary and data Guidance for the investigator
c) Discussion of published reports on related products
d) Potential costs of the clinical trial.
The investigator’s brochure should include all of the following except
d) Potential costs of the clinical trial.
Which of the following would not be classified as an SAE?
a) An anaphylactic event which needed an emergency room visit
b) An acute renal failure, which resulted in an increased hospitalization stay of one day
c) A stroke which occurred during a clinical trial
d) Severe hallucinations caused by the ingestion of a recreational drug
Which of the following would not be classified as an SAE?
d) Severe hallucinations caused by the ingestion of a recreational drug
In response to new preclinical studies a sponsor revises the Investigator’s Brochure which leads to changes in the inclusion and exclusion criteria and informs the Pl of these changes. The Pl or CRC should
a) File an amendment to the IRB detailing the change
b) Make revisions in the informed consent
c) Reconsent existing enrolled subjects
d) All of the above
In response to new preclinical studies a sponsor revises the Investigator’s Brochure which leads to changes in the inclusion and exclusion criteria and informs the Pl of these changes. The Pl or CRC should
d) All of the above
a) File an amendment to the IRB detailing the change
b) Make revisions in the informed consent
c) Reconsent existing enrolled subjects
The person who the subject should contact for research subject rights is
a) The person noted in the consent form for such contact
b) A person other than the principal investigator
c) Usually an IRB appointed Research Subject Advocate described in the consent form
d) All of the above
The person who the subject should contact for research subject rights is
a) The person noted in the consent form for such contact
The person who should be contacted regarding a medical emergency experienced at home by a clinical trial subject is
a) Always the principal investigator
b) The sponsor’s medical safety officer
c) The research coordinator
d) The person designated for contact for medical matters on the consent form
The person who should be contacted regarding a medical emergency experienced at home by a clinical trial subject is
d) The person designated for contact for medical matters on the consent form
The best way for a Pl to inform a subject about a placebo in a double-blind trial includes all of the following except
a) There is a fifty percent chance that you may be in a group that does not receive the investigational drug
b) Because of the restrictions of the study I cannot tell you if you are in the group receiving drug or a sugar pill
c) You will receive the same attention regardless of whether you are in the group receiving a drug or a sugar pill
d) You need not concern yourself about whether you are receiving the drug or a sugar pill as we cannot tell you if the clinical trial has had any beneficial effect.
The best way for a Pl to inform a subject about a placebo in a double-blind trial includes all of the following except
d) You need not concern yourself about whether you are receiving the drug or a sugar pill as we cannot tell you if the clinical trial has had any beneficial effect.
According to ICH all of the following are essential documents except
a) Delegation of authority forms
b) Certificates of analysis for new batches of investigational drugs
c) Normal values for the analytes being tested
d) Conflict of interest information for core team members
According to ICH all of the following are essential documents except
d) Conflict of interest information for core team members
A clinical trial in which the only the research pharmacist knows the identity of the test article being given to subjects is a
a) Single-blind trial
b) Double-blind trial
c) Open label trial
d) Crossover design trial
A clinical trial in which the only the research pharmacist knows the identity of the test article being given to subjects is a
b) Double-blind trial
A subject on a clinical trial for GI reflux disease experiences several bowel movements and is hospitalized for dehydration. He has been on the test drug for three weeks and the event is thought by the PI to be related to the test drug. The event should be reported in all of the following ways except
a) As a serious adverse event to the IRB
b) To the sponsor on the appropriate CRF
c) By the sponsor to the regulatory agency
d) To the family physician for symptom management
A subject on a clinical trial for GI reflux disease experiences several bowel movements and is hospitalized for dehydration. He has been on the test drug for three weeks and the event is thought by the PI to be related to the test drug. The event should be reported in all of the following ways except
d) To the family physician for symptom management
An SAE experienced by a subject on a test drug for a clinical trial should be reported to
a) Immediately to the sponsor
b) To the regulatory agency within 7 calendar days
c) To the IRB usually in five days or sooner depending on institutional policy
d) All of the above
An SAE experienced by a subject on a test drug for a clinical trial should be reported to
d) All of the above
a) Immediately to the sponsor
b) To the regulatory agency within 7 calendar days
c) To the IRB usually in five days or sooner depending on institutional policy
In consenting an adult illiterate subjects who cannot read or write English the consent process should include
a) Reading the consent form to the subject
b) Having the subject make a mark “X” on the subject signature line
c) Have an impartial witness present
d) All of the above
In consenting an adult illiterate subjects who cannot read or write English the consent process should include
d) All of the above
a) Reading the consent form to the subject
b) Having the subject make a mark “X” on the subject signature line
c) Have an impartial witness present
A medically competent subject who has recently undergone physical injury in an accident to his writing hand signs the consent form with an “x” The consent process should include
a) An impartial witness
b) The signature of a legal guardian
c) A medical counselor
d) The signature of a family member
A medically competent subject who has recently undergone physical injury in an accident to his writing hand signs the consent form with an “x” The consent process should include
b) The signature of a legal guardian
About 15 subjects were enrolled in a clinical trial. The trial is most likely
a) Phase l
b) Phase ll
c) Phase III
d) Phase IV
About 15 subjects were enrolled in a clinical trial. The trial is most likely
a) Phase l
A clinical trial requires five CT scans in the period of one year. For the disease condition only one CT scan per year is indicated. The situation requires
a) The radiation safety committee evaluation and approval prior to IRB approval
b) Statement about radiation risk in the consent form
c) A consideration of an alternative imaging technique if possible.
d) All of the above
A clinical trial requires five CT scans in the period of one year. For the disease condition only one CT scan per year is indicated. The situation requires
d) All of the above
a) The radiation safety committee evaluation and approval prior to IRB approval
b) Statement about radiation risk in the consent form
c) A consideration of an alternative imaging technique if possible
A subject being screened for a clinical trial of a drug for allergic rhinitis presents with a heart rate of 110 beats per minute. Tachycardia is not an exclusion criterion for the study. The CRC should
a) Ask the sponsor’s medical safety officer if the subject should be enrolled
b) Do a repeat measurement of heart rate, in two weeks or more, to see if the symptom is repeatable
c) Ask the subject if he has experienced any symptoms of a rapid heart beat
d) All of the above
A subject being screened for a clinical trial of a drug for allergic rhinitis presents with a heart rate of 110 beats per minute. Tachycardia is not an exclusion criterion for the study. The CRC should
d) All of the above
a) Ask the sponsor’s medical safety officer if the subject should be enrolled
b) Do a repeat measurement of heart rate, in two weeks or more, to see if the symptom is repeatable
c) Ask the subject if he has experienced any symptoms of a rapid heart beat
During the course of a clinical trial the CRC notices that the Hct values have been consistently low in several subjects. Upon further investigation it was discovered that the lab assistant was storing the samples under his desk and sending the entire batch for analysis once every week. The CRC should
a) Immediately inform the Pl
b) File a protocol deviation with the IRB
c) Inform the sponsor
d) Arrange to have the lab assistant retrained or disciplined
e) Initiate a CAPA plan
f) All of the above
During the course of a clinical trial the CRC notices that the Hct values have been consistently low in several subjects. Upon further investigation it was discovered that the lab assistant was storing the samples under his desk and sending the entire batch for analysis once every week. The CRC should
f) All of the above
a) Immediately inform the Pl
b) File a protocol deviation with the IRB
c) Inform the sponsor
d) Arrange to have the lab assistant retrained or disciplined
e) Initiate a CAPA plan
A CRC has scheduled a first visit for a subject for an IRB approved study. When the patient arrives the CRC notices that the IRB approval letter is missing a date. The CRC should do all of the following except
a) Reschedule the visit
b) Contact the IRB and ask for a dated letter
c) Inform the Pl
d) File an unanticipated event report with the IRB
A CRC has scheduled a first visit for a subject for an IRB approved study. When the patient arrives the CRC notices that the IRB approval letter is missing a date. The CRC should do all of the following except
d) File an unanticipated event report with the IRB